BioXcel Therapeutics, Inc. announced it has raised $14 million in equity financing, providing the company with approximately $35 million in cash to support its pivotal Phase 3 SERENITY At-Home trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results